

October 1, 2018

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001.

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

**Sub: Update on intimation regarding the Orthopaedic Business**

Reference is made to the intimation made to the Stock exchanges on August 10, 2018 by the Company in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, about the approval of the Board for the transaction with True North for Orthopaedic and Pain Management Business.

We now wish to inform you that the Company has completed the formalities.

You are requested to take the same on record.

Thanking You.

Yours faithfully,  
For Glenmark Pharmaceuticals Ltd.



Harish Kuber  
Company Secretary & Compliance Officer